Dog Vaccines Market Trends, Size, Growth, Revenue, Analysis, Challenges and Future Outlook
Dog Vaccines Market Growth, Size, Trends Analysis - By Vaccine Type, By Disease Type, By Route of Administration, By Duration of Immunity, By Component, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Jan-2025 | Report ID: HLCA2507 | Pages: 1 - 246 | Formats*: |
| Category : Healthcare | |||
Global Dog Vaccines Market Introduction and Overview
According to SPER Market Research, the Global Dog Vaccines Market is estimated to reach USD 3.79 billion by 2034 with a CAGR of 6.68%.
The report includes an in-depth analysis of the Global Dog Vaccines Market, including market size and trends, product mix, Applications, and supplier analysis. The market for dog vaccines is projected to expand at a compound annual growth rate (CAGR) of 6.68% between 2025 and 2034. The market is growing as a result of rising pet ownership and pet humanization, which encourages treating pets like members of the family and providing them with the finest comfort and care. Pet owners are more inclined to spend money on veterinary care and vaccinations since they view their animals as part of the family, which increases demand for both core and non-core vaccines. Pet humanization results in more knowledgeable pet owners who recognize the value of vaccination schedules and make sure dogs get the vaccinations they need on time.
By Vaccine Type Insights
The modified live segment held the largest revenue share in 2024. The market for attenuated live vaccines is driven by their long-term immunity against illnesses. These vaccines protect against all parvoviruses and canine adenovirus-2. For instance, Nobivac, from Merck & Co, Inc, immunizes dogs against canine distemper virus, canine adenovirus type 1, canine parvovirus, and canine parainfluenza virus.
By Disease Type Insights
The canine infectious respiratory disease complex (CIRDC) segment generated the highest revenue in 2024. The presence of various causes for CIRDC has led to new vaccine development. For example, Merck Animal Health launched the Nobivac Intra-Trac Oral BbPi in September 2022, the first oral vaccine for Bordetella bronchiseptica and canine parainfluenza virus. Controlling the spread of these diseases is vital for protecting dogs' respiratory health and preventing outbreaks.
By Route of Administration Insights
Injectables held the highest revenue share in 2024 as they are the most popular among doctors and pet owners due to their precise dose administration. MSD Animal Health introduced Nobivac Respira Bb in March 2021 to prevent Bordetella bronchiseptica. A single dose protects dogs for seven months after the initial course and for one year after the booster dose.
By Duration of Immunity Insights
The one-year segment had the largest revenue share in 2024. The vaccine offers a year of immunity to help prevent common infections without needing regular booster shots. This gives dog owners an easier option, likely boosting market growth. Most core vaccines for dogs provide immunity for about a year, requiring annual booster shots for continued protection.
By Component Insights
The combined vaccine segment had the largest revenue share in 2024 and is expected to grow quickly from 2025 to 2030. These vaccines protect against multiple diseases and reduce the number of shots needed for dogs. This convenience is likely to boost demand in the dog vaccine market by making vaccinations easier. Furthermore, using one vaccine lowers veterinary costs and is cheaper for pet owners than getting individual vaccines. Combined vaccines also lessen stress for dogs, encouraging timely vaccinations.
By Distribution Channel Insights
Hospital and clinic pharmacies held the largest market share in 2024. They are important for distributing vaccines, making them accessible to pet owners. These pharmacies often collaborate with suppliers to provide vaccines for diseases like rabies and parvovirus. They are usually part of veterinary hospitals and clinics, where professionals give the vaccines, ensuring proper handling and storage.
By Regional Insights
The global market for dog vaccines was dominated by North America in 2024. The area is home to a number of significant dog vaccination companies. Additionally, rising pet ownership rates and greater knowledge of pet preventative healthcare are major drivers of this market expansion.
Market Competitive Landscape:
Leading companies in this sector are using strategies including mergers and acquisitions, partnerships and collaborations, and the introduction of new products and trials to increase their revenue share. For instance, in June 2023, MebGenesis Inc. and Boehringer Ingelheim International GmbH collaborated to develop canine monoclonal antibodies. Similarly, in June 2022, Zoetis Services LLC acquired Basepaws Inc, likely expanding its line of precision animal health products. It is anticipated that these developments would lead to an increase in this market.
Recent Developments:
- The CSIC-developed vaccine against canine leishmaniasis, a recombinant vaccine to fight the parasite that causes skin ulcers and severe inflammation of the liver and spleen, was released by the Zendal group in March 2024.
- Merck & Co., Inc.'s ongoing commitment to rabies prevention was demonstrated in June 2024 when it launched the NOBIVAC NXT Rabies portfolio in Canada, which comprises NOBIVAC NXT Canine-3 Rabies and NOBIVAC NXT Feline-3 Rabies.
- Merck Animal Health released the first oral vaccination in September 2022 that targets Bordetella bronchiseptica and the para-influenza virus, two canine respiratory infections.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Vaccine Type, By Disease Type, By Route of Administration, By Duration of Immunity, By Component, By Distribution Channel |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Boehringer Ingelheim International GmbH, Zoetis Services LLC, Merck & Co., Inc, Elanco, Hester Biosciences Limited, Virbac, Bioveta a.s, Brilliant Bio Pharma, Heska Corporation, Zendal Group. |
Key Topics Covered in the Report:
- Global Dog Vaccines Market Size (FY’2021-FY’2034)
- Overview of Global Dog Vaccines Market
- Segmentation of Global Dog Vaccines Market By Vaccine Type (Modified/ Attenuated Live, Inactivated, Other Vaccines)
- Segmentation of Global Dog Vaccines Market By Disease Type (Canine Distemper, Canine Infectious Respiratory Disease Complex, Canine Parvovirosis/ Parvovirus Disease, Canine Leptospirosis, Canine Lyme Disease, Infectious Canine Hepatitis, Canine Rabies, Other Diseases)
- Segmentation of Global Dog Vaccines Market By Route of Administration (Injectables, Intranasal, Oral)
- Segmentation of Global Dog Vaccines Market By Duration of Immunity (1 Year, 3 Year, Others)
- Segmentation of Global Dog Vaccines Market By Component (Combined Vaccines, Mono Vaccines)
- Segmentation of Global Dog Vaccines Market By Distribution Channel (Retail, E-Commerce, Hospital/Clinic Pharmacies)
- Statistical Snap of Global Dog Vaccines Market
- Expansion Analysis of Global Dog Vaccines Market
- Problems and Obstacles in Global Dog Vaccines Market
- Competitive Landscape in the Global Dog Vaccines Market
- Details on Current Investment in Global Dog Vaccines Market
- Competitive Analysis of Global Dog Vaccines Market
- Prominent Players in the Global Dog Vaccines Market
- SWOT Analysis of Global Dog Vaccines Market
- Global Dog Vaccines Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs2.2. Market size estimation2.2.1. Top-down and Bottom-up approach2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats5.2. PESTEL Analysis5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape5.3. PORTERs Five Forces5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Dog Vaccines Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Dog Vaccines Market
7. Global Dog Vaccines Market, By Vaccine Type (USD Million) 2021-2034
7.1. Modified/ Attenuated Live7.2. Inactivated (Killed)7.3. Other Vaccines
8. Global Dog Vaccines Market, By Disease Type (USD Million) 2021-2034
8.1. Canine Distemper8.2. Canine Infectious Respiratory Disease Complex (CIRDC)8.3. Canine Parvovirosis/ Parvovirus Disease8.4. Canine Leptospirosis8.5. Canine Lyme Disease8.6. Infectious Canine Hepatitis8.7. Canine Rabies8.8. Other Diseases
9. Global Dog Vaccines Market, By Route of Administration (USD Million) 2021-2034
9.1. Injectables9.2. Intranasal9.3. Oral
10. Global Dog Vaccines Market, By Duration of Immunity (USD Million) 2021-2034
10.1. 1 Year10.2. 3 Year10.3. Others
11. Global Dog Vaccines Market, By Component (USD Million) 2021-2034
11.1. Combined Vaccines11.2. Mono Vaccines
12. Global Dog Vaccines Market, By Distribution Channel (USD Million) 2021-2034
12.1. Retail12.2. E-Commerce12.3. Hospital/Clinic Pharmacies
13. Global Dog Vaccines Market (USD Million) 2021-2034
13.1. Global Dog Vaccines Market Size and Market Share
14. Global Dog Vaccines Market, By Region (USD Million) 2021-2034
14.1. Asia-Pacific14.1.1. Australia14.1.2. China14.1.3. India14.1.4. Japan14.1.5. South Korea14.1.6. Rest of Asia-Pacific14.2. Europe14.2.1. France14.2.2. Germany14.2.3. Italy14.2.4. Spain14.2.5. United Kingdom14.2.6. Rest of Europe14.3. Middle East and Africa14.3.1. Kingdom of Saudi Arabia14.3.2. United Arab Emirates14.3.3. Qatar14.3.4. South Africa14.3.5. Egypt14.3.6. Morocco14.3.7. Nigeria14.3.8. Rest of Middle-East and Africa14.4. North America14.4.1. Canada14.4.2. Mexico14.4.3. United States14.5. Latin America14.5.1. Argentina14.5.2. Brazil14.5.3. Rest of Latin America
15. Company Profile
15.1. Zoetis15.1.1. Company details15.1.2. Financial outlook15.1.3. Product summary15.1.4. Recent developments15.2. Boehringer Ingelheim International GmbH15.2.1. Company details15.2.2. Financial outlook15.2.3. Product summary15.2.4. Recent developments15.3. Merck & Co., Inc15.3.1. Company details15.3.2. Financial outlook15.3.3. Product summary15.3.4. Recent developments15.4. Elanco15.4.1. Company details15.4.2. Financial outlook15.4.3. Product summary15.4.4. Recent developments15.5. Virbac15.5.1. Company details15.5.2. Financial outlook15.5.3. Product summary15.5.4. Recent developments15.6. Bioveta a.s15.6.1. Company details15.6.2. Financial outlook15.6.3. Product summary15.6.4. Recent developments15.7. Hester Biosciences Limited15.7.1. Company details15.7.2. Financial outlook15.7.3. Product summary15.7.4. Recent developments15.8. Brilliant Bio Pharma15.8.1. Company details15.8.2. Financial outlook15.8.3. Product summary15.8.4. Recent developments15.9. Heska Corporation15.9.1. Company details15.9.2. Financial outlook15.9.3. Product summary15.9.4. Recent developments15.10. Zendal Group15.10.1. Company details15.10.2. Financial outlook15.10.3. Product summary15.10.4. Recent developments
15.11. Others
16. Conclusion
17. List of Abbreviations
18. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Dog Vaccines Market is projected to reach USD 3.79 billion by 2034, growing at a CAGR of 6.68% during the forecast period.
Dog Vaccines Market grew in Market size from 2025. The Market is expected to reach USD 3.79 billion by 2034, at a CAGR of 6.68% during the forecast period.
Dog Vaccines Market CAGR of 6.68% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Dog Vaccines Market size is USD 3.79 billion from 2025 to 2034.
Dog Vaccines Market is covered By Vaccine Type, By Disease Type, By Route of Administration, By Duration of Immunity, By Component, By Distribution Channel
The North America is anticipated to have the highest Market share in the Dog Vaccines Market.
The Key players in the Market include Companies Covered Boehringer Ingelheim International GmbH, Zoetis Services LLC, Merck & Co., Inc, Elanco, Hester Biosciences Limited, Virbac, Bioveta a.s, Brilliant Bio Pharma, Heska Corporation, Zendal Group.
The high cost of advanced diabetes drugs and the financial burden of treating diabetes remain major obstacles to market growth, despite the fact that numerous drugs have been approved for the condition and that governments and industry players are launching numerous initiatives.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
